Sorafenib, a multikinase inhibitor, is effective in vitro against non-Hodgkin lymphoma and synergizes with the mTOR inhibitor rapamycin

相似書籍

• Sorafenib, a dual Raf kinase/vascular endothelial growth factor receptor inhibitor has significant anti-myeloma activity and synergizes with common anti-myeloma drugs
  由: Ramakrishnan, V, et al.
  出版: (2009)
• MRK003, a Gamma Secretase Inhibitor exhibits promising in vitro pre-clinical activity in Multiple Myeloma and Non Hodgkin's Lymphoma
  由: Ramakrishnan, Vijay, et al.
  出版: (2011)
• TG101209, a novel JAK2 inhibitor, has significant in-vitro activity in multiple myeloma and displays preferential cytotoxicity for CD45+ myeloma cells
  由: Ramakrishnan, Vijay, et al.
  出版: (2010)
• The multikinase inhibitor Sorafenib enhances glycolysis and synergizes with glycolysis blockade for cancer cell killing
  由: Tesori, Valentina, et al.
  出版: (2015)
• Multiple mechanisms contribute to the synergistic anti-myeloma activity of the pan-histone deacetylase inhibitor LBH589 and the rapalog RAD001
  由: Ramakrishnan, Vijay, et al.
  出版: (2014)